AbCellera to Lead Development of Rapid Response Platform ...

AbCellera Awarded Multi-Year Contract to Lead the Development of ...

Over the four-year contract, AbCellera will receive up to USD $30 million in funding to establish an end-to-end platform for rapid pandemic ...

AbCellera will receive up to USD $30 million in funding to establish an end-to-end platform for rapid pandemic response.

AbCellera's Rapid Pandemic Response Platform Contributes to the ...

VANCOUVER, British Columbia, June 1, 2020 – AbCellera today announced that LY-CoV555, the lead antibody from the collaboration between ...

AbCellera awarded contract to develop a rapid response platform ...

Over the four-year contract, AbCellera will receive up to USD $30 million in funding to establish an end-to-end platform for rapid pandemic ...

AbCellera and Lilly to Co-develop Antibody Therapies for the ...

The collaboration will leverage AbCellera's rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) ...

AbCellera Announces Partnership with NIAID Vaccine Research ...

Central to AbCellera's platform is a microfluidic technology that allows for deep mining of natural immune responses, yielding large and diverse ...

AbCellera to develop response platform for viral pandemics

AbCellera Biologics has received a four-year contract from the US Defense Advanced Research Projects Agency (DARPA) for the development of a ...

Rapid response through the entrepreneurial capabilities of ... - Nature

AbCellera's AI-powered antibody discovery platform allows for faster, lower cost and more accurate antibody discovery, improving upon existing ...

DARPA-funded AbCellera to pursue mAbs to treat ... - BioCentury

... AbCellera in 2018 to lead the development of the Pandemic Prevention Platform (P3) program, a rapid response platform against pandemic viral threats. After ...

To Develop Coronavirus Treatment, Lilly Taps AbCellera Antibody ...

patients to recover from COVID-19, AbCellera, a Canadian therapeutic antibody discovery company, put its rapid pandemic response platform to ...

AbCellera Named to Fast Company's Annual List of the World's Most ...

Combined with Celium™, AbCellera's powerful antibody visualization and exploration software, the platform can search and analyze natural immune ...

AbCellera on X: "AbCellera Biologics awarded multi-year contract ...

... Lead the Development of a Rapid Response Platform Against... Under DARPA's Pandemic Prevention Platform (P3) program, AbCellera will apply its state-of-the ...

Dousing the Pandemic's Flames

When AbCellera became a participant in DARPA's P3 (Pandemic Prevention Platform) program in 2018, the aim was to build a pandemic-ready, rapid ...

AbCellera Provides COVID-19 Program Update with the Start of ...

A first-of-its-kind, the Lilly-sponsored trial will use customized mobile research units to conduct the study at long-term care facilities ...

AbCellera's Rapid Pandemic Response Platform Contributes to the ...

Article content. VANCOUVER, British Columbia — AbCellera today announced that LY-CoV555, the lead antibody from the collaboration between ...

Vancouver-based AbCellera on Leading Edge of COVID-19 Drug ...

Though antibody development can take years to reach clinical trials, the results of AbCellera and Eli Lilly's work will be fast-tracked with the ...

AbCellera-Discovered Bamlanivimab Together with Etesevimab ...

AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 ...

News Releases - AbCellera Biologics Inc. - Investor Relations

Emergency use authorization now includes post-exposure prophylaxis to prevent COVID-19 in certain people who have been exposed to someone ...

AbCellera-Discovered Antibody Prevented COVID-19 in Nursing ...

AbCellera's pandemic response capabilities were developed over the past two years as part of the Defense Advanced Research Projects Agency ( ...

AbCellera-Discovered Antibody Granted Interim Authorization by ...

Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the ...